<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="epb42-spherocytosis" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">epb42-spherocytosis</book-part-id>
      <title-group>
        <title><italic toggle="yes">EPB42</italic>-Related Hereditary Spherocytosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kalfa</surname>
            <given-names>Theodosia A</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Cancer and Blood Diseases Institute<break/>Division of Hematology<break/>Cincinnati Children's Hospital Medical Center and University of Cincinnati Medical School<break/>Cincinnati, Ohio</aff>
          <email>theodosia.kalfa@cchmc.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Connor</surname>
            <given-names>Jessica A</given-names>
          </name>
          <degrees>MS</degrees>
          <aff>Counsyl, Inc<break/>South San Francisco, California</aff>
          <email>jconnor@counsyl.com</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Begtrup</surname>
            <given-names>Amber H</given-names>
          </name>
          <degrees>PhD, FACMG</degrees>
          <aff>GeneDx, Inc<break/>Gaithersburg, Maryland</aff>
          <email>abegtrup@genedx.com</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>13</day>
          <month>3</month>
          <year>2014</year>
        </date>
        <date date-type="updated">
          <day>10</day>
          <month>11</month>
          <year>2016</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="cyclic-n" document-type="chapter">
<italic toggle="yes">ELANE</italic>-Related Neutropenia</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="exosc3-pc-hypo-p" document-type="chapter"><italic toggle="yes">EXOSC3</italic>-Related Pontocerebellar Hypoplasia</related-object>
      <abstract id="epb42-spherocytosis.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">EPB42</italic>-related hereditary spherocytosis (EPB42-HS) is a chronic non-immune hemolytic anemia that is usually of mild to moderate severity. EPB42-HS can present with jaundice as early as the first 24 hours of life or can present later in childhood with anemia resulting from a hemolytic crisis or aplastic crisis (usually associated with a viral infection). In addition to the hematologic manifestations, serious complications include splenomegaly that can become evident in early childhood and cholelithiasis that usually becomes evident in the second or third decade of life.</p>
          <p>Typical laboratory findings in EPB42-HS include anemia (decreased hemoglobin [Hgb] level) and reticulocytosis (increased percent of reticulocytes), with high mean corpuscular hemoglobin concentration (MCHC), presence of spherocytes in the peripheral blood smear, significantly decreased or absent haptoglobin, mildly increased osmotic fragility, and decreased maximal deformability index (DI<sub>max</sub>) with increased O<sub>min</sub> (osmolality at which 50% of red blood cells hemolyze) measured by ektacytometry.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of EPB42-HS is established by the identification of biallelic pathogenic variants in <italic toggle="yes">EPB42</italic>.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Treatment for mild EPB42-HS (Hgb 11-15 g/dL, reticulocytes 3%-8%) includes folic acid supplementation (400 &#x000b5;g 1x daily until age 1 year; 1 mg 1x daily thereafter) and RBC transfusion as needed for a hemolytic or aplastic crisis. Although splenectomy is rarely indicated in EPB42-HS since disease severity is usually mild or moderate, it may be recommended in those with moderately severe EPB42-HS (Hgb 6-8 g/dL, reticulocytes &#x02265;10%) who are older than age five years when quality of life is compromised. Although curative, splenectomy entails a long-term increased risk for potential life-threatening infection, and thus requires complete immunizations before the procedure and antibiotic prophylaxis after. Affected individuals with a history of cholelithiasis should have cholecystectomy at the time of splenectomy.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> See <italic toggle="yes">Treatment of manifestations</italic> for information on use of splenectomy.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Regular immunizations to prevent infections that can trigger a hemolytic or aplastic crisis. Iron overload is a risk especially if frequent transfusions are required; treatment with an iron chelator is typically begun after about ten transfusions (which correlate to a serum ferritin concentration of approximately 1000 ng/mL).</p>
          <p><italic toggle="yes">Surveillance:</italic> Neonates require monitoring of serum bilirubin concentration during the first week of life and infants require monitoring of Hgb in the first two to four months of life to screen for significant anemia. Those dependent on frequent transfusions and those receiving iron chelation therapy require monitoring of serum ferritin concentration. Abdominal ultrasound examination to evaluate for cholelithiasis either when symptoms are present or, when hemolysis is significant, by age ten to 12 years, and every five to ten years thereafter.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Any preparations containing iron; however, if iron studies have documented iron deficiency, treatment with supplemental iron must be closely monitored and then discontinued when iron stores have been repleted. Avoidance of contact sports is recommended in those with splenomegaly; of note, acute or excessive splenomegaly is a greater risk than chronic mild splenomegaly.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> When EPB42-HS has been diagnosed in a family member, the following is recommended for at-risk sibs: (1) Neonates at risk require monitoring of serum bilirubin concentration during the first week of life so that treatment for hyperbilirubinemia can be instituted promptly; and (2) infants at risk require monitoring in the first two to four months of life for significant anemia, which may require RBC transfusion and initiation of folate supplementation. Laboratory evaluation (CBC and reticulocyte count, blood smear, osmotic fragility or ektacytometry) and/or molecular genetic testing for the <italic toggle="yes">EPB42</italic> pathogenic variants in the family (if known) is appropriate for at-risk relatives.</p>
          <p><italic toggle="yes">Pregnancy management:</italic> Folic acid supplementation (800-1000 &#x000b5;g daily) is necessary; monitoring for exacerbation of anemia with CBC and reticulocyte count is recommended.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>EPB42-HS is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="epb42-spherocytosis.Diagnosis">
        <title>Diagnosis</title>
        <sec id="epb42-spherocytosis.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p><italic toggle="yes">EPB42</italic>-related hereditary spherocytosis (EPB42-HS) <bold>should be suspected</bold> in individuals with any of the following clinical and supportive laboratory findings:</p>
          <p>
            <bold>Clinical findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Pallor and/or fatigue due to anemia, which is usually of mild to moderate severity</p>
            </list-item>
            <list-item>
              <p>Jaundice</p>
              <list list-type="bullet">
                <list-item>
                  <p>Usually intermittent and caused by unconjugated hyperbilirubinemia resulting from exacerbated hemolysis</p>
                </list-item>
                <list-item>
                  <p>In rare cases, caused by conjugated hyperbilirubinemia resulting from biliary obstruction</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Splenomegaly</p>
            </list-item>
            <list-item>
              <p>Cholelithiasis in the second or third decade of life</p>
            </list-item>
            <list-item>
              <p>Family history consistent with autosomal recessive inheritance</p>
              <p>Note: Absence of a family history of EPB42-HS does not preclude the diagnosis.</p>
            </list-item>
          </list>
          <p>
            <bold>Supportive laboratory findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Complete blood count</bold> consistent with:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Chronic, non-immune hemolytic anemia (decreased hemoglobin with reticulocytosis), usually of mild to moderate severity</p>
                  <list list-type="bullet">
                    <list-item>
                      <p>Decreased hemoglobin (Hgb) level (See <xref ref-type="table" rid="epb42-spherocytosis.T.severity_of_heredi">Table 1</xref> for Hgb levels that define the severity of hereditary spherocytosis.)</p>
                      <p>Note: Hgb values in EPB42-HS may also vary depending on the clinical status of the affected individual (baseline or during a hemolytic or aplastic crisis).</p>
                    </list-item>
                    <list-item>
                      <p>Increased percent of reticulocytes as well as increased absolute reticulocyte count (ARC) (See <xref ref-type="table" rid="epb42-spherocytosis.T.severity_of_heredi">Table 1</xref> for percent of reticulocytes that define the severity of hereditary spherocytosis.)</p>
                      <p>Note: Percent of reticulocytes may vary (depending on baseline or crisis status) from 2.5 to greater than 10% (or even normal or low when in aplastic crisis).</p>
                    </list-item>
                  </list>
                </list-item>
                <list-item>
                  <p>High mean corpuscular hemoglobin concentration (MCHC). Normal values are typically 31-37 g/dL. Values in HS are usually 35.5-37.5 g/dL.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>
                <bold>Negative (i.e., normal) direct anti-globulin test (DAT)</bold>
              </p>
              <p>Note: DAT should always be evaluated in a person with newly diagnosed hemolytic anemia to evaluate for an acute immune-mediated (acquired) hemolytic anemia.</p>
            </list-item>
            <list-item>
              <p><bold>Peripheral blood smear</bold> demonstrating presence of spherocytes and occasionally a few ovalocytes and elliptocytes</p>
              <p>Note: The term spherocyte refers to the sphere-shaped red blood cells (with a decreased surface/volume ratio) that characterize the RBC cytoskeleton disorders (see <xref ref-type="sec" rid="epb42-spherocytosis.Differential_Diagnos">Differential Diagnosis</xref>).</p>
            </list-item>
            <list-item>
              <p><bold>Significantly decreased or absent haptoglobin.</bold> After age six months normal haptoglobin values are 16-200 mg/dL. In HS, haptoglobin is typically undetectable; however, haptoglobin can be normal in the presence of concurrent inflammation (as it is an acute phase reactant).</p>
            </list-item>
            <list-item>
              <p><bold>Mildly increased osmotic fragility</bold> (as in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105174/figure/F1/">Figure 1B</ext-link> of <xref ref-type="bibr" rid="epb42-spherocytosis.REF.hammill.2011.780">Hammill et al [2011]</xref>; see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105174/">full text</ext-link>)</p>
            </list-item>
            <list-item>
              <p><bold>Decreased maximal deformability index (DI<sub>max</sub>)</bold> and <bold>increased O<sub>min</sub></bold> (osmolality at which 50% of red blood cells hemolyze) measured by ektacytometry, giving a typical HS curve [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.clark.1983.899">Clark et al 1983</xref>, <xref ref-type="bibr" rid="epb42-spherocytosis.REF.hammill.2011.780">Hammill et al 2011</xref>]</p>
            </list-item>
          </list>
          <table-wrap id="epb42-spherocytosis.T.severity_of_heredi" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Severity of Hereditary Spherocytosis</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Severity</th>
                  <th id="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Hgb (g/dL)</th>
                  <th id="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reticulocytes (%)</th>
                  <th id="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Splenectomy</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Mild</bold>
                  </td>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">11-15</td>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">3-8</td>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Not necessary</td>
                </tr>
                <tr>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Moderate</bold>
                  </td>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">8-11.5</td>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;8</td>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Consider if activity level &#x00026; quality of life are decreased</td>
                </tr>
                <tr>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Moderately severe</bold>
                  </td>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">6-8</td>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02265;10</td>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Indicated at age &#x0003e;5 yrs</td>
                </tr>
                <tr>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Severe</bold>
                  </td>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;6</td>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02265;10</td>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Indicated at age &#x0003e;3 yrs</td>
                </tr>
                <tr>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Normal&#x000a0;<sup>1</sup></bold>
                  </td>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">11.7-15.7 (adult females) 13.3-17.7 (adult males)</td>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">0.5-1.5&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Based on table by <xref ref-type="bibr" rid="epb42-spherocytosis.REF.eber.2004">Eber &#x00026; Lux [2004]</xref></p>
              </fn>
              <fn id="epb42-spherocytosis.TF.1.1">
                <label>1. </label>
                <p>Normal values may vary somewhat depending on age and gender.</p>
              </fn>
              <fn id="epb42-spherocytosis.TF.1.2">
                <label>2. </label>
                <p>ARC 45-90 x 10<sup>3</sup>/&#x000b5;L</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="epb42-spherocytosis.Establishing_the_Dia">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of <italic toggle="yes">EPB42</italic>-related hereditary spherocytosis <bold>is established</bold> in a proband by the identification of biallelic pathogenic variants in <italic toggle="yes">EPB42</italic> (see <xref ref-type="table" rid="epb42-spherocytosis.T.molecular_genetic">Table 2</xref>).</p>
          <p>Molecular genetic testing approaches can include <bold>single-gene testing</bold> or use of a <bold>multi-gene panel</bold>:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">EPB42</italic> is performed.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">EPB42</italic> and other genes of interest (see <xref ref-type="sec" rid="epb42-spherocytosis.Differential_Diagnos">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
            </list-item>
          </list>
          <table-wrap id="epb42-spherocytosis.T.molecular_genetic" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Molecular Genetic Testing Used in <italic toggle="yes">EPB42</italic>-Related Hereditary Spherocytosis</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_epb42-spherocytosis.T.molecular_genetic_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_epb42-spherocytosis.T.molecular_genetic_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_epb42-spherocytosis.T.molecular_genetic_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_epb42-spherocytosis.T.molecular_genetic_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">EPB42</italic>
                  </td>
                  <td headers="hd_h_epb42-spherocytosis.T.molecular_genetic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_epb42-spherocytosis.T.molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">16/16&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_epb42-spherocytosis.T.molecular_genetic_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_epb42-spherocytosis.T.molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>6,&#x000a0;7</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="epb42-spherocytosis.TF.2.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="epb42-spherocytosis" object-id="epb42-spherocytosis.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="epb42-spherocytosis.TF.2.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="epb42-spherocytosis.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="epb42-spherocytosis.TF.2.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="epb42-spherocytosis.TF.2.4">
                <label>4. </label>
                <p>Most are case reports with no information on the number of individuals with hereditary spherocytosis who did not have pathogenic variants identified in <italic toggle="yes">EPB42</italic> [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.kanzaki.1997.522">Kanzaki et al 1997</xref>, <xref ref-type="bibr" rid="epb42-spherocytosis.REF.toye.2008.5380">Toye et al 2008</xref>].</p>
              </fn>
              <fn id="epb42-spherocytosis.TF.2.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="epb42-spherocytosis.TF.2.6">
                <label>6. </label>
                <p>No data on detection rate of gene-targeted deletion/duplication analysis are available.</p>
              </fn>
              <fn id="epb42-spherocytosis.TF.2.7">
                <label>7. </label>
                <p>The only gross deletion reported to date is a 32-base pair deletion [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.hammill.2011.780">Hammill et al 2011</xref>] that is expected to be detectable by sequence analysis.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="epb42-spherocytosis.Clinical_Characteris">
        <title>Clinical Characteristics</title>
        <sec id="epb42-spherocytosis.Clinical_Description">
          <title>Clinical Description</title>
          <p>Children with <italic toggle="yes">EPB42</italic>-related hereditary spherocytosis (EPB42-HS) frequently present within the first 24 hours of life with jaundice that requires treatment with phototherapy or, rarely, exchange transfusion to prevent kernicterus. They may also present later in childhood with anemia resulting from a hemolytic crisis or aplastic crisis usually associated with a viral infection.</p>
          <p>Toddlers with hereditary spherocytosis are occasionally found to have age-related iron deficiency anemia; however, the anemia fails to completely resolve with iron supplementation and reticulocytosis persists.</p>
          <p>As with all forms of mild or moderate hereditary spherocytosis (see <xref ref-type="table" rid="epb42-spherocytosis.T.severity_of_heredi">Table 1</xref> for definitions), EPB42-HS can be more severe in the first four to six months of life, requiring regular red blood cell transfusions. Thus, frequent transfusions during the first few months of life do not necessarily correlate with disease severity later on.</p>
          <p>EPB42-HS, if not recognized during infancy or early childhood, may be diagnosed later in life as a mild (Hgb 11-15 g/dL) to moderate (Hgb 8-11.5 g/dL) chronic hemolytic anemia (see <xref ref-type="table" rid="epb42-spherocytosis.T.severity_of_heredi">Table 1</xref>), with jaundice, splenomegaly, and cholelithiasis at a relatively young age [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.eber.2004">Eber &#x00026; Lux 2004</xref>].</p>
        </sec>
        <sec id="epb42-spherocytosis.GenotypePhenotype_Co">
          <title>Genotype-Phenotype Correlations</title>
          <p>Homozygosity for <xref ref-type="table" rid="epb42-spherocytosis.T.selected_epb42_pat">p.Ala142Thr</xref> has been found most commonly in Japan and was reported to lead to moderately severe HS, with Hgb as low as 6.1 g/dL [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.bouhassira.1992.1846">Bouhassira et al 1992</xref>]. A non-Japanese affected individual with the same genotype was reported in Italy; her phenotype included moderate hemolytic anemia from birth and splenomegaly [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.perrotta.1999.660">Perrotta et al 1999</xref>].</p>
          <p>Homozygosity for <xref ref-type="table" rid="epb42-spherocytosis.T.selected_epb42_pat">p.Ala142Thr</xref> or homozygosity for <xref ref-type="table" rid="epb42-spherocytosis.T.selected_epb42_pat">p.Asp175Tyr</xref> results in atypical HS with the presence of ovalostomatocytes in addition to few spherocytes in the blood smear. Hemolysis may be mild to moderately severe and improves after splenectomy [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.bouhassira.1992.1846">Bouhassira et al 1992</xref>, <xref ref-type="bibr" rid="epb42-spherocytosis.REF.kanzaki.1995.165">Kanzaki et al 1995</xref>].</p>
          <p>Compound heterozygosity for <xref ref-type="table" rid="epb42-spherocytosis.T.selected_epb42_pat">p.Ala142Thr</xref> with another <italic toggle="yes">EPB42</italic> pathogenic variant causes typical HS with microspherocytes in the blood smear and increased osmotic fragility [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.takaoka.1994.527">Takaoka et al 1994</xref>, <xref ref-type="bibr" rid="epb42-spherocytosis.REF.kanzaki.1995.165">Kanzaki et al 1995</xref>]. Case reports of individuals with other <italic toggle="yes">EPB42</italic> pathogenic variants also indicate mild to moderate HS with only occasional need for blood transfusion [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.hayette.1995.250">Hayette et al 1995</xref>, <xref ref-type="bibr" rid="epb42-spherocytosis.REF.van_den_akker.2010.1278">van den Akker et al 2010</xref>, <xref ref-type="bibr" rid="epb42-spherocytosis.REF.hammill.2011.780">Hammill et al 2011</xref>].</p>
          <p>One individual homozygous for the null <xref ref-type="table" rid="epb42-spherocytosis.T.selected_epb42_pat">c.950delG</xref> variant (resulting in premature termination of the transcript and lack of production of any viable erythrocyte membrane protein band 4.2 &#x02013; known in recent literature as protein 4.2) developed a strong antibody response against protein 4.2 after multiple red blood cell transfusions for gastrointestinal bleeding, causing alloimmune hemolytic anemia [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.beauchampnicoud.2000.19">Beauchamp-Nicoud et al 2000</xref>]. Antibody development has not been described yet following red blood cell transfusion in persons with other <italic toggle="yes">EPB42</italic> pathogenic variants, although in most of the cases of <italic toggle="yes">EPB42</italic>-associated HS no protein 4.2 is detectable in the RBC membrane [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.satchwell.2009.201">Satchwell et al 2009</xref>].</p>
        </sec>
        <sec id="epb42-spherocytosis.Prevalence">
          <title>Prevalence</title>
          <p>Hereditary spherocytosis is the most common inherited anemia in individuals of northern European ancestry, with a prevalence of 1:2000 or higher when the very mild forms (which are frequently underdiagnosed) are included. The worldwide prevalence is lower.</p>
          <p><italic toggle="yes">EPB42</italic>-associated hereditary spherocytosis is responsible for 40%-50% of hereditary spherocytosis in Japan, where the carrier frequency of <xref ref-type="table" rid="epb42-spherocytosis.T.selected_epb42_pat">p.Ala142Thr</xref> among healthy persons is as high as 3% [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.yawata.1994.131">Yawata 1994</xref>, <xref ref-type="bibr" rid="epb42-spherocytosis.REF.yawata.2000.118">Yawata et al 2000</xref>].</p>
          <p>In other populations, EPB42-HS accounts for 5% or less of HS [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.eber.2004">Eber &#x00026; Lux 2004</xref>, <xref ref-type="bibr" rid="epb42-spherocytosis.REF.perrotta.2008.1411">Perrotta et al 2008</xref>].</p>
        </sec>
      </sec>
      <sec id="epb42-spherocytosis.Genetically_Related">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">EPB42.</italic></p>
      </sec>
      <sec id="epb42-spherocytosis.Differential_Diagnos">
        <title>Differential Diagnosis</title>
        <p>The initial evaluation of a person with hemolytic anemia typically includes: complete blood count (CBC) and reticulocyte count; blood smear review; direct anti-globulin test (DAT) and indirect Coombs to evaluate for auto-immune (or, in an infant, allo-immune) hemolytic anemia; hemoglobin electrophoresis; and G6PD enzyme activity (especially in males). Osmotic fragility testing and/or ektacytometry can focus the diagnosis within an erythrocyte membrane disorder. <xref ref-type="fig" rid="epb42-spherocytosis.F1">Figure 1</xref> demonstrates ektacytometry results typical of hereditary spherocytosis. Classification of hereditary spherocytosis based on genetic etiology is shown in <xref ref-type="table" rid="epb42-spherocytosis.T.classification_of">Table 3</xref>.</p>
        <p>For the individual with non-immune hemolytic anemia, the differential diagnosis includes the other causes of hereditary hemolytic anemia, including the other forms of hereditary spherocytosis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Other RBC membrane disorders</p>
          </list-item>
          <list-item>
            <p>Hereditary spherocytosis (see <xref ref-type="table" rid="epb42-spherocytosis.T.classification_of">Table 3</xref>)</p>
          </list-item>
          <list-item>
            <p>Hereditary elliptocytosis, stomatocytosis, or Southeast Asian ovalocytosis, since individuals homozygous for either <xref ref-type="table" rid="epb42-spherocytosis.T.selected_epb42_pat">p.Ala142Thr</xref> or <xref ref-type="table" rid="epb42-spherocytosis.T.selected_epb42_pat">p.Asp175Tyr</xref> in <italic toggle="yes">EPB42</italic> are reported to also have ovalocytes and stomatocytes in the blood smear. Note: Splenectomy has been associated with significant and life-threatening thrombotic events in persons with hereditary stomatocytosis (overhydrated or dehydrated/xerocytosis); therefore, differentiation between hereditary stomatocytosis and <italic toggle="yes">EPB42</italic>-associated HS (EPB42-HS) is necessary if splenectomy is contemplated.</p>
          </list-item>
          <list-item>
            <p>Hemoglobin disorders. EPB42-HS is usually easily distinguished from <related-object link-type="booklink" source-id="gene" document-id="b-thal" document-type="chapter">&#x003b2;-thalassemia</related-object> or <related-object link-type="booklink" source-id="gene" document-id="a-thal" document-type="chapter">HbH disease</related-object>, both of which are characterized by microcytosis and hypochromia. Chronic mild hemolytic anemias due to unstable hemoglobin chains may require further evaluation, including hemoglobin analysis by electrophoresis or HPLC and/or globin gene sequencing.</p>
          </list-item>
          <list-item>
            <p>Erythrocyte enzymopathies, such as glucose-6-phospate dehydrogenase (G6PD) deficiency (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/300908">OMIM</ext-link>) or pyruvate kinase (PK) deficiency (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/266200">OMIM</ext-link>); typically distinguished from EPB42-HS by absence of spherocytic RBC morphology and by normal ektacytometry or osmotic fragility. Some erythrocyte enzyme disorders (e.g., triose phosphate isomerase [TPI] deficiency [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/615512">OMIM</ext-link>] or phosphoglycerate kinase 1 [PGK1] deficiency [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/300653">OMIM</ext-link>]) also have neurologic and musculoskeletal manifestations. Enzymatic activity assays and/or gene sequencing establishes the diagnosis.</p>
          </list-item>
          <list-item>
            <p>Congenital dyserythropoietic anemia, especially type II when it presents with a mild phenotype (i.e., mild anemia, reticulocytosis [although suboptimal], jaundice, and splenomegaly) (See <related-object link-type="booklink" source-id="gene" document-id="cda1" document-type="chapter">Congenital Dyserythropoietic Anemia Type I</related-object>.)</p>
          </list-item>
        </list>
        <table-wrap id="epb42-spherocytosis.T.classification_of" orientation="portrait" position="anchor">
          <label>Table 3. </label>
          <caption>
            <p>Classification of Hereditary Spherocytosis</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Locus</th>
                <th id="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene</th>
                <th id="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein</th>
                <th id="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mode of Inheritance</th>
                <th id="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Severity&#x000a0;<sup>1</sup></th>
                <th id="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_6" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Comment</th>
                <th id="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_7" valign="middle" align="left" scope="col" rowspan="1" colspan="1">OMIM</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">SPH1</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">
                  <italic toggle="yes">ANK1</italic>
                </td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">Ankyrin-1</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Mild-moderate</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"/>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_7" rowspan="2" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/182900">182900</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_4" valign="middle" colspan="1" align="left" scope="row" rowspan="1">AR</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Moderately severe-severe</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">Often transfusion-dependent</td>
              </tr>
              <tr>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">SPH2</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">
                  <italic toggle="yes">SPTB</italic>
                </td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">Spectrin beta chain, erythrocytic</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Mild-moderate</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"/>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_7" rowspan="2" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/616649">616649</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_4" valign="middle" colspan="1" align="left" scope="row" rowspan="1">AR</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Severe</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">A fatal infantile case has been described</td>
              </tr>
              <tr>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">SPH3</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">SPTA1</italic>
                </td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Spectrin alpha chain, erythrocytic 1</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Severe</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">Transfusion-dependent</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/270970">270970</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">SPH4</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">SLC4A1</italic>
                </td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Band 3 (anion transport protein)</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Mild-moderate</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">Certain <italic toggle="yes">SLC4A1</italic> pathogenic variants cause disease only when biallelic</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/612653">612653</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">SPH5</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">EPB42</italic>
                </td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Protein 4.2&#x000a0;<sup>2</sup></td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Mild-moderate&#x000a0;<sup>3</sup></td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">A moderately severe case has been described</td>
                <td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/612690">612690</ext-link>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>AD = autosomal dominant</p>
            </fn>
            <fn>
              <p>AR = autosomal recessive</p>
            </fn>
            <fn id="epb42-spherocytosis.TF.3.1">
              <label>1. </label>
              <p>Defined in <xref ref-type="table" rid="epb42-spherocytosis.T.severity_of_heredi">Table 1</xref></p>
            </fn>
            <fn id="epb42-spherocytosis.TF.3.2">
              <label>2. </label>
              <p>Significant decrease or absence of erythrocyte membrane protein band 4.2 (known in recent literature simply as protein 4.2) in erythrocytes of persons with HS may also be secondary to biallelic <italic toggle="yes">SLC4A1</italic> pathogenic variants (SPH4) by either decreasing band 3 in the red blood cell membrane [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.toye.2008.5380">Toye et al 2008</xref>] or affecting the band 3 binding site for protein 4.2 [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.kanzaki.1997.522">Kanzaki et al 1997</xref>].</p>
            </fn>
            <fn id="epb42-spherocytosis.TF.3.3">
              <label>3. </label>
              <p><italic toggle="yes">SPH5</italic> is typically milder than the other forms of hereditary spherocytosis inherited in an AR manner (i.e., SPH1 [AR] and SPH3).</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="epb42-spherocytosis.Management">
        <title>Management</title>
        <sec id="epb42-spherocytosis.Evaluations_Followin">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with <italic toggle="yes">EPB42</italic>-related hereditary spherocytosis (EPB42-HS), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Hemoglobin concentration and reticulocyte count to evaluate severity of disease</p>
            </list-item>
            <list-item>
              <p>Serum bilirubin concentration</p>
            </list-item>
            <list-item>
              <p>Transfusion history</p>
            </list-item>
            <list-item>
              <p>Serum ferritin concentration to evaluate iron load status</p>
            </list-item>
            <list-item>
              <p>Abdominal ultrasound examination to evaluate:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Spleen size if physical examination is not conclusive due to body habitus or if contact sports are contemplated</p>
                </list-item>
                <list-item>
                  <p>For evidence of cholelithiasis when symptoms are present. If hemolysis is significant a screening ultrasound may be considered after age 10-12 years, even without symptoms.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="epb42-spherocytosis.Treatment_of_Manifes">
          <title>Treatment of Manifestations</title>
          <p>Detailed management <xref ref-type="sec" rid="epb42-spherocytosis.References">guidelines</xref> for hereditary spherocytosis (HS) have been published [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.eber.2004">Eber &#x00026; Lux 2004</xref>, <xref ref-type="bibr" rid="epb42-spherocytosis.REF.boltonmaggs.2012">Bolton-Maggs et al 2012</xref>].</p>
          <p><bold>Conservative management</bold> recommendations for mild EPB42-HS (Hgb 11-15 g/dL, reticulocytes 3-8%) (<xref ref-type="table" rid="epb42-spherocytosis.T.severity_of_heredi">Table 1</xref>) include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Folic acid supplementation (400 &#x000b5;g 1x daily until age 1 year; then 1 mg 1x daily thereafter)</p>
            </list-item>
            <list-item>
              <p>Avoidance of iron supplementation unless concurrent iron deficiency is confirmed with iron studies, in which case treatment with supplemental iron should be carefully monitored and discontinued after iron stores are repleted to avoid iron overload</p>
              <p>Note: Hereditary spherocytosis (as all chronic hemolytic anemias) involves an increased risk for iron overload even with oral iron supplementation (see <xref ref-type="sec" rid="epb42-spherocytosis.Prevention_of_Second">Prevention of Secondary Complications</xref>).</p>
            </list-item>
            <list-item>
              <p>Red blood cell (RBC) transfusion, if needed, for hemolytic or aplastic crisis</p>
            </list-item>
          </list>
          <p><bold>Splenectomy</bold> is rarely indicated in EPB42-HS, as disease severity is usually mild or moderate. However, when disease is moderate (see <xref ref-type="table" rid="epb42-spherocytosis.T.severity_of_heredi">Table 1</xref>) and normal activity or quality of life is compromised, splenectomy can be performed after age five years provided that hereditary stomatocytosis has been ruled out (see <xref ref-type="sec" rid="epb42-spherocytosis.Differential_Diagnos">Differential Diagnosis</xref>). Note: Total splenectomy is not recommended for children younger than age five years even if the child requires frequent transfusions for moderately severe HS (which is rare in EPB42-HS).</p>
          <p>Although splenectomy is curative, it entails potential long-term increased risk for life-threatening infection and, thus, should not be undertaken before the risks and benefits have been fully weighed [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.casale.2011.627">Casale &#x00026; Perrotta 2011</xref>].</p>
          <p>Ideally, the following immunizations should be completed before splenectomy:</p>
          <list list-type="bullet">
            <list-item>
              <p>Immunizations for <italic toggle="yes">Streptococcus pneumoniae</italic> with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) and for <italic toggle="yes">N. meningitidis</italic> with a meningococcal conjugate vaccine against the serogroups A, C, W, and Y (MenACWY) at least two weeks before splenectomy. A two-dose primary series of MenACWY is recommended 8-12 weeks apart [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.committee_on_infectious_diseases.2011.1213">Committee on Infectious Diseases 2011</xref>].</p>
            </list-item>
            <list-item>
              <p>Prevnar-13<sup>&#x000ae;</sup> and <italic toggle="yes">H. influenzae type b</italic> vaccines during infancy per general pediatric immunization guidelines</p>
            </list-item>
          </list>
          <p>The incidence of post-splenectomy sepsis varies among studies. Although low overall, the risk for sepsis, a life-threatening complication, is higher than in the general population [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.iolascon.1998.240">Iolascon et al 1998</xref>]. To reduce the risk of infection post splenectomy, the following are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Give booster vaccination for PPSV23 five years after the first dose. No more than two PPSV23 doses are recommended [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.pekka_nuorti.2010">Pekka Nuorti &#x00026; Whitney 2010</xref>].</p>
            </list-item>
            <list-item>
              <p>Give booster dose for meningococcal vaccine three years after the primary series if the primary two-dose series was given between ages two and six years and every five years for persons whose two-dose primary series or booster dose was given at age seven years or older [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.cohn.2013">Cohn et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>Serogroup B meningococcal vaccines are recommended for people age ten years and older with history of splenectomy.</p>
            </list-item>
          </list>
          <p>Controversy exists regarding the duration of use of antibiotics for prophylaxis post-splenectomy: some hematologists recommend prophylactic antibiotics for the first three years post splenectomy and others for life [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.eber.2004">Eber &#x00026; Lux 2004</xref>]. The antibiotics recommended are penicillin V-K 250 mg twice daily or erythromycin for those allergic to penicillin.</p>
          <p>In any case, an individual who has undergone splenectomy needs immediate medical attention for fever and prompt use of IV antibiotics with good coverage for encapsulated organisms (typically ceftriaxone in doses adequate to treat meningitis: 100 mg/kg/day up to 2 g/day in single daily dose).</p>
          <p><bold>Partial splenectomy</bold> appears to be associated with a lesser risk for post-splenectomy sepsis and a sustained decrease (although not elimination) of hemolysis and may be preferable for young children if the surgeon is experienced in the procedure [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.badermeunier.2001.399">Bader-Meunier et al 2001</xref>]. An ongoing prospective observation of more than 100 children in a congenital hemolytic anemia multi-institutional registry, who have undergone total or partial splenectomy, may elucidate better the risks and benefits of each procedure [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.rice.2012.684">Rice et al 2012</xref>, <xref ref-type="bibr" rid="epb42-spherocytosis.REF.rice.2015.187">Rice et al 2015</xref>].</p>
          <p>Antibiotic prophylaxis may be discontinued one year after partial splenectomy if immune splenic function is adequate as assessed by pit count (percentage of pitted or pocked red cells) or the uptake of radioactive colloid by the spleen [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.eber.2004">Eber &#x00026; Lux 2004</xref>].</p>
          <p>
            <bold>Cholecystectomy</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The gallbladder should be removed in affected individuals undergoing splenectomy who have a history of cholelithiasis.</p>
            </list-item>
            <list-item>
              <p>In children who require cholecystectomy, concurrent splenectomy is not recommended automatically any more. The need for splenectomy should be assessed on a case-by-case basis and the indication of splenectomy justified independently [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.boltonmaggs.2012">Bolton-Maggs et al 2012</xref>, <xref ref-type="bibr" rid="epb42-spherocytosis.REF.ruparel.2014.433">Ruparel et al 2014</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="epb42-spherocytosis.Prevention_of_Primar">
          <title>Prevention of Primary Manifestations</title>
          <p><bold>Splenectomy</bold> is rarely indicated in EPB42-HS, as disease severity is usually mild or moderate. Note: When indicated, splenectomy is curative; however, it can have potential life-threatening complications (see <xref ref-type="sec" rid="epb42-spherocytosis.Treatment_of_Manifes">Treatment of Manifestations</xref>). Note: Total splenectomy is not recommended for children younger than age five years even if the child requires frequent transfusions for moderately severe HS (which is rare in EPB42-HS).</p>
        </sec>
        <sec id="epb42-spherocytosis.Prevention_of_Second">
          <title>Prevention of Secondary Complications</title>
          <p><bold>Regular immunizations</bold> are recommended as well as influenza vaccine annually to prevent infections that can precipitate hemolytic or aplastic crisis.</p>
          <p><bold>Iron overload</bold> and its associated chronic organ failure are risks with any chronic hemolytic anemia especially if frequent transfusions are required.</p>
          <list list-type="bullet">
            <list-item>
              <p>Treatment with an iron chelator should be implemented, typically after about ten transfusions (which correlate to a serum ferritin concentration of approximately 1000 ng/mL).</p>
            </list-item>
            <list-item>
              <p>The effectiveness of chelation should be monitored by evaluation of liver iron by T<sub>2</sub>*-weighted MRI or FerriScan<sup>&#x000ae;</sup> so that the dose of iron chelator can be adjusted appropriately.</p>
            </list-item>
          </list>
        </sec>
        <sec id="epb42-spherocytosis.Surveillance">
          <title>Surveillance</title>
          <p>Neonates with HS require monitoring of serum bilirubin concentration during the first week of life so that treatment for hyperbilirubinemia can be instituted promptly to avoid complications such as kernicterus.</p>
          <p>Infants with HS require monitoring in the first two to four months of life for significant anemia, which may require RBC transfusion</p>
          <p>Those dependent on frequent transfusions require at least annual measurement of serum ferritin concentration.</p>
          <p>If iron chelation is required secondary to frequent transfusions in children too young to undergo splenectomy, appropriate monitoring for toxicity and effectiveness of chelation treatment is necessary [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.musallam.2013.64">Musallam et al 2013</xref>].</p>
          <p>When hemolysis is significant, ultrasound examination to evaluate for cholelithiasis is indicated by age ten to twelve years, and every five to ten years thereafter.</p>
        </sec>
        <sec id="epb42-spherocytosis.AgentsCircumstances">
          <title>Agents/Circumstances to Avoid</title>
          <p>Any preparations containing iron should be avoided (see <xref ref-type="sec" rid="epb42-spherocytosis.Treatment_of_Manifes">Treatment of Manifestations</xref>).</p>
          <p>Contact sports are not advisable in those with splenomegaly; of note, acute or excessive splenomegaly is a greater risk than chronic mild splenomegaly.</p>
        </sec>
        <sec id="epb42-spherocytosis.Evaluation_of_Relati">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to perform laboratory evaluation of the phenotype (CBC and reticulocyte count, blood smear, osmotic fragility or ektacytometry) and clarify the genetic status of apparently asymptomatic older and younger sibs of an affected individual by molecular genetic testing of the <italic toggle="yes">EPB42</italic> pathogenic variants in the family in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.</p>
          <list list-type="bullet">
            <list-item>
              <p>Neonates require monitoring of serum bilirubin concentration during the first week of life so that treatment for hyperbilirubinemia can be instituted promptly to avoid complications such as kernicterus.</p>
            </list-item>
            <list-item>
              <p>Infants require monitoring in the first two to four months of life for significant anemia, which may require RBC transfusion and initiation of folate supplementation</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="epb42-spherocytosis.Related_Genetic_Coun">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="epb42-spherocytosis.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Folic acid supplementation (800-1000 &#x000b5;g daily) is necessary in pregnant women with chronic hemolytic anemias such as EPB42-HS.</p>
          <p>Monitoring for exacerbation of anemia with CBC and reticulocyte count is recommended in pregnant women with HS, as hemolytic crisis and persistent anemia have been reported during pregnancy, especially in women who have not undergone splenectomy [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.pajor.1993.37">Pajor et al 1993</xref>].</p>
        </sec>
        <sec id="epb42-spherocytosis.Therapies_Under_Inve">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="epb42-spherocytosis.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="epb42-spherocytosis.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">EPB42</italic>-related hereditary spherocytosis (EPB42-HS) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="epb42-spherocytosis.Risk_to_Family_Membe">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">EPB42</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with EPB42-HS are obligate heterozygotes (carriers) for an <italic toggle="yes">EPB42</italic> pathogenic variant.</p>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier of an <italic toggle="yes">EPB42</italic> pathogenic variant.</p>
        </sec>
        <sec id="epb42-spherocytosis.Carrier_Heterozygote">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">EPB42</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="epb42-spherocytosis.Related_Genetic_Coun">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="epb42-spherocytosis.Evaluation_of_Relati">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="epb42-spherocytosis.Prenatal_Testing_and">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">EPB42</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for EPB42-HS are possible options.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="epb42-spherocytosis.Resources">
        <title>Resources</title>
      </sec>
      <sec id="epb42-spherocytosis.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="epb42-spherocytosis.Molecular_Genetic_Pa">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Erythrocyte membrane protein band 4.2 (also known as protein 4.2), encoded by <italic toggle="yes">EPB42,</italic> is a major component of the red blood cell cytoskeleton and maintains the stability and flexibility of red cells through interactions with other key RBC proteins, many of which (in their pathogenic forms) also cause hereditary spherocytosis.</p>
          <p>Protein 4.2 is a part of the ankyrin-band 3 complex, connecting band 3 protein (encoded by <italic toggle="yes">SLC4A1</italic>; see <xref ref-type="table" rid="epb42-spherocytosis.T.classification_of">Table 3</xref>, SPH4<italic toggle="yes">)</italic> with the CD47 and Rhesus protein complex antigens. Protein 4.2 supports physical associations between the cytoskeleton and the membrane lipid bilayer [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.bruce.2003.4180">Bruce et al 2003</xref>].</p>
          <p>Protein 4.2 interacts with spectrin, a tetramer comprising an alpha-subunit (see <xref ref-type="table" rid="epb42-spherocytosis.T.classification_of">Table 3</xref>, SPH3) and beta-subunit (see <xref ref-type="table" rid="epb42-spherocytosis.T.classification_of">Table 3</xref>, SPH2), which is the largest protein in the RBC cytoskeleton [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.mandal.2002.841">Mandal et al 2002</xref>, <xref ref-type="bibr" rid="epb42-spherocytosis.REF.korsgren.2010.4757">Korsgren et al 2010</xref>].</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">EPB42</italic> (previously known as <italic toggle="yes">ELB42</italic>) spans approximately 23 kb of genomic DNA. The longer transcript isoform (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000119.2">NM_000119.2</ext-link>) has 2554 bp and 13 exons. Alternative splicing produces a shorter transcript variant (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_001114134.1">NM_001114134.1</ext-link>) excluding the last 90 nucleotides of exon 1. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="epb42-spherocytosis" object-id="epb42-spherocytosis.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic allelic variants.</bold> To date, at least 13 distinct <italic toggle="yes">EPB42</italic> pathogenic variants have been described, including missense, nonsense, frameshift, and splicing variants and small deletions. More than 50% of the identified pathogenic variants have been in the Japanese population [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.bouhassira.1992.1846">Bouhassira et al 1992</xref>, <xref ref-type="bibr" rid="epb42-spherocytosis.REF.yawata.2000.118">Yawata et al 2000</xref>]. Affected individuals from Europe [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.perrotta.1999.660">Perrotta et al 1999</xref>, <xref ref-type="bibr" rid="epb42-spherocytosis.REF.van_den_akker.2010.1278">van den Akker et al 2010</xref>] and North America [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.hammill.2011.780">Hammill et al 2011</xref>] have also been identified.</p>
          <p>The p.Ala142Thr variant has been observed in a homozygous state in affected individuals. While this variant has a carrier frequency of approximately 3% in persons of Japanese ancestry, it was also found in an affected individual from central Italy who had no Japanese ancestry [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.perrotta.1999.660">Perrotta et al 1999</xref>]. Although the frequency in the Japanese population is likely explained by a founder effect, the apparent random occurrence of this variant in another population may be explained by the fact that the G&#x0003e;A transition occurs within a CpG site on the antisense DNA strand [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.elango.2008.e1000015">Elango et al 2008</xref>].</p>
          <table-wrap id="epb42-spherocytosis.T.selected_epb42_pat" orientation="portrait" position="anchor">
            <label>Table 4. </label>
            <caption>
              <p>Selected <italic toggle="yes">EPB42</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_epb42-spherocytosis.T.selected_epb42_pat_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_epb42-spherocytosis.T.selected_epb42_pat_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_epb42-spherocytosis.T.selected_epb42_pat_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_epb42-spherocytosis.T.selected_epb42_pat_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.424G&#x0003e;A</td>
                  <td headers="hd_h_epb42-spherocytosis.T.selected_epb42_pat_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala142Thr<break/>(4.2 Nippon)</td>
                  <td headers="hd_h_epb42-spherocytosis.T.selected_epb42_pat_1_1_1_3" rowspan="6" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000119.2">NM_000119.2</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000110.2">NP_000110.2</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_epb42-spherocytosis.T.selected_epb42_pat_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.523G&#x0003e;T</td>
                  <td headers="hd_h_epb42-spherocytosis.T.selected_epb42_pat_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asp175Tyr<break/>(4.2 Komatsu)</td>
                </tr>
                <tr>
                  <td headers="hd_h_epb42-spherocytosis.T.selected_epb42_pat_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.920C&#x0003e;T</td>
                  <td headers="hd_h_epb42-spherocytosis.T.selected_epb42_pat_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr307Ile<break/>(4.2 Cincinnati)</td>
                </tr>
                <tr>
                  <td headers="hd_h_epb42-spherocytosis.T.selected_epb42_pat_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.929G&#x0003e;A</td>
                  <td headers="hd_h_epb42-spherocytosis.T.selected_epb42_pat_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg310Gln<break/>(4.2 Tozeur)</td>
                </tr>
                <tr>
                  <td headers="hd_h_epb42-spherocytosis.T.selected_epb42_pat_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.949C&#x0003e;T</td>
                  <td headers="hd_h_epb42-spherocytosis.T.selected_epb42_pat_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg317Cys<break/>(4.2 Shiga)</td>
                </tr>
                <tr>
                  <td headers="hd_h_epb42-spherocytosis.T.selected_epb42_pat_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.950delG</td>
                  <td headers="hd_h_epb42-spherocytosis.T.selected_epb42_pat_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Frameshift<break/>(4.2 Nancy)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="epb42-spherocytosis.TF.4.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> The long and short <italic toggle="yes">EPB42</italic> transcript variants encode the two protein 4.2 isoforms: the 74-kd minor isoform of 721 amino acids (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000110.2">NP_000110.2</ext-link>) and the 72-kd major isoform of 691 amino acids (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_001107606.1">NP_001107606.1</ext-link>). Although homologous to transglutaminases, protein 4.2 lacks two of the catalytic triad residues required for transglutaminase activity, and thus is an enzymatically inactive protein [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.toye.2005.4088">Toye et al 2005</xref>].</p>
          <p>Protein 4.2 is a major component of the red blood cell cytoskeleton and maintains the stability and flexibility of red cells through interactions with other key RBC proteins, many of which (in their pathogenic forms) also cause hereditary spherocytosis (see <xref ref-type="sec" rid="epb42-spherocytosis.Molecular_Genetic_Pa">Molecular Genetic Pathogenesis</xref> and <xref ref-type="table" rid="epb42-spherocytosis.T.classification_of">Table 3</xref>).</p>
          <p>Aggravation of hemolysis during the neonatal period has been attributed to the presence of fetal hemoglobin, which has poor affinity for 2,3-diphosphoglycerate (2,3-DPG), resulting in increased free intracellular 2,3-DPG that destabilizes the spectrin-protein 4.1 interactions and intensifies hemolysis [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.mentzer.1987.943">Mentzer et al 1987</xref>].</p>
          <p>Protein 4.2 interacts with its binding partners in the RBC cytoskeleton via specific domains. Protein 4.2 amino acid residues 187-211 of the long isoform <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/protein/NP_000110.2">NP_000110.2</ext-link> have been shown to mediate binding to ankyrin (see <xref ref-type="table" rid="epb42-spherocytosis.T.classification_of">Table 3</xref>, SPH1) and band 3, bridging these two proteins [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.su.2006.159">Su et al 2006</xref>] and linking band 3 and the lipid bilayer with the cytoskeletal scaffold.</p>
          <p><bold>Abnormal gene product.</bold> More than half of the identified <italic toggle="yes">EPB42</italic> pathogenic variants are predicted to result in complete loss of protein, which is presumed to be the mechanism of pathogenesis.</p>
          <p>At least six distinct pathogenic missense variants have been observed. Functional analyses include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>In vitro binding studies of the <italic toggle="yes">EPB42</italic> alleles encoding <xref ref-type="table" rid="epb42-spherocytosis.T.selected_epb42_pat">p.Arg310Gln</xref> and <xref ref-type="table" rid="epb42-spherocytosis.T.selected_epb42_pat">p.Asp175Tyr</xref> demonstrated altered binding of protein 4.2 to band 3 [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.toye.2005.4088">Toye et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p>The <xref ref-type="table" rid="epb42-spherocytosis.T.selected_epb42_pat">p.Thr307Ile</xref> [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.hammill.2011.780">Hammill et al 2011</xref>] and p.Arg317Cys [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.kanzaki.1995.165">Kanzaki et al 1995</xref>] pathogenic variants within the putative band 3 binding domain lead to complete absence of protein 4.2, presumably due to proteolysis before incorporation into the membrane.</p>
            </list-item>
            <list-item>
              <p>In in vitro studies the <xref ref-type="table" rid="epb42-spherocytosis.T.selected_epb42_pat">p.Ala142Thr</xref> allele binds band 3 normally, suggesting that this pathogenic variant causes 4.2 deficiency independent of band 3 [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.toye.2005.4088">Toye et al 2005</xref>]. The p.Ala142Thr variant in the homozygous state (observed in four unrelated Japanese individuals) results in RBC ghost membranes that are almost completely deficient for protein 4.2 [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.bouhassira.1992.1846">Bouhassira et al 1992</xref>].</p>
            </list-item>
          </list>
          <p>Of note, although band 3 levels in protein 4.2-deficient RBCs are not altered, the extractability and lateral diffusion of band 3 are significantly increased [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.rybicki.1996.2745">Rybicki et al 1996</xref>].</p>
        </sec>
      </sec>
      <sec id="epb42-spherocytosis.References">
        <title>References</title>
        <sec id="epb42-spherocytosis.Published_Guidelines">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="epb42-spherocytosis.Published_Guidelines.reflist0">
            <ref id="epb42-spherocytosis.REF.boltonmaggs.2012">
              <mixed-citation publication-type="web">Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ. Guidelines for the diagnosis and management of hereditary spherocytosis--2011 update. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2011.08921.x/full">online</ext-link>. 2012. Accessed 11-7-16.</mixed-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.boltonmaggs.2004">
              <mixed-citation publication-type="web">Bolton-Maggs PH, Stevens RF, Dodd NJ, Lamont G, Tittensor P, King MJ. Guidelines for the diagnosis and management of hereditary spherocytosis. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2004.05052.x/full">online</ext-link>. 2004. Accessed 11-7-16.</mixed-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.eber.2004">
              <mixed-citation publication-type="web">Eber S, Lux SE. Hereditary spherocytosis--defects in proteins that connect the membrane skeleton to the lipid bilayer. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.seminhematol.org/article/S0037-1963%2804%2900003-4/abstract">online</ext-link> (login or institutional access required). 2004. Accessed 11-7-16.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="epb42-spherocytosis.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="epb42-spherocytosis.Literature_Cited.reflist0">
            <ref id="epb42-spherocytosis.REF.badermeunier.2001.399">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bader-Meunier</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gauthier</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Archambaud</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cynober</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mielot</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dommergues</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warszawski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohandas</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tchernia</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Long-term evaluation of the beneficial effect of subtotal splenectomy for management of hereditary spherocytosis.</article-title>
                <source>Blood.</source>
                <year>2001</year>
                <volume>97</volume>
                <fpage>399</fpage>
                <lpage>403</lpage>
                <pub-id pub-id-type="pmid">11154215</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.beauchampnicoud.2000.19">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beauchamp-Nicoud</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morle</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lutz</surname>
                    <given-names>HU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stammler</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Agulles</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petermann-Khder</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iolascon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perrotta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cynober</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tchernia</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delaunay</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baudin-Creuza</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <article-title>Heavy transfusions and presence of an anti-protein 4.2 antibody in 4. 2(-) hereditary spherocytosis (949delG).</article-title>
                <source>Haematologica.</source>
                <year>2000</year>
                <volume>85</volume>
                <fpage>19</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">10629586</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.boltonmaggs.2012.37">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bolton-Maggs</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langer</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iolascon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tittensor</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <article-title>Guidelines for the diagnosis and management of hereditary spherocytosis--2011 update.</article-title>
                <source>Br J Haematol.</source>
                <year>2012</year>
                <volume>156</volume>
                <fpage>37</fpage>
                <lpage>49</lpage>
                <pub-id pub-id-type="pmid">22055020</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.bouhassira.1992.1846">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bouhassira</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yawata</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ata</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanzaki</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qiu</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagel</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rybicki</surname>
                    <given-names>AC</given-names>
                  </name>
                </person-group>
                <article-title>An alanine-to-threonine substitution in protein 4.2 cDNA is associated with a Japanese form of hereditary hemolytic anemia (protein 4.2NIPPON).</article-title>
                <source>Blood.</source>
                <year>1992</year>
                <volume>79</volume>
                <fpage>1846</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">1558976</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.bruce.2003.4180">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bruce</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beckmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chasis</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delaunay</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohandas</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anstee</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanner</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <article-title>A band 3-based macrocomplex of integral and peripheral proteins in the RBC membrane.</article-title>
                <source>Blood.</source>
                <year>2003</year>
                <volume>101</volume>
                <fpage>4180</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12531814</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.casale.2011.627">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Casale</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perrotta</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Splenectomy for hereditary spherocytosis: complete, partial or not at all?</article-title>
                <source>Expert Rev Hematol.</source>
                <year>2011</year>
                <volume>4</volume>
                <fpage>627</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">22077527</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.clark.1983.899">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohandas</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shohet</surname>
                    <given-names>SB</given-names>
                  </name>
                </person-group>
                <article-title>Osmotic gradient ektacytometry: comprehensive characterization of red cell volume and surface maintenance.</article-title>
                <source>Blood.</source>
                <year>1983</year>
                <volume>61</volume>
                <fpage>899</fpage>
                <lpage>910</lpage>
                <pub-id pub-id-type="pmid">6831052</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.cohn.2013">
              <mixed-citation publication-type="web">Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE. Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf">online</ext-link>. 2013. Accessed 11-8-16.</mixed-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.committee_on_infectious_diseases.2011.1213">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>Committee on Infectious Diseases</collab>
                </person-group>
                <article-title>Meningococcal conjugate vaccines policy update: booster dose recommendations.</article-title>
                <source>Pediatrics.</source>
                <year>2011</year>
                <volume>128</volume>
                <fpage>1213</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22123893</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.eber.2004.118">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eber</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lux</surname>
                    <given-names>SE</given-names>
                  </name>
                </person-group>
                <article-title>Hereditary spherocytosis--defects in proteins that connect the membrane skeleton to the lipid bilayer.</article-title>
                <source>Semin Hematol.</source>
                <year>2004</year>
                <volume>41</volume>
                <fpage>118</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">15071790</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.elango.2008.e1000015">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elango</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vigoda</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yi</surname>
                    <given-names>SV</given-names>
                  </name>
                </person-group>
                <article-title>Mutations of different molecular origins exhibit contrasting patterns of regional substitution rate variation.</article-title>
                <source>PLoS Comput Biol.</source>
                <year>2008</year>
                <volume>4</volume>
                <fpage>e1000015</fpage>
                <pub-id pub-id-type="pmid">18463707</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.hammill.2011.780">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hammill</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Risinger</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joiner</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keddache</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalfa</surname>
                    <given-names>TA</given-names>
                  </name>
                </person-group>
                <article-title>Compound heterozygosity for two novel mutations in the erythrocyte protein 4.2 gene causing spherocytosis in a Caucasian patient.</article-title>
                <source>Br J Haematol.</source>
                <year>2011</year>
                <volume>152</volume>
                <fpage>780</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">21275958</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.hayette.1995.250">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hayette</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dhermy</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>dos Santos</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bozon</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drenckhahn</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alloisio</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Texier</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delaunay</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morl&#x000e9;</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>A deletional frameshift mutation in protein 4.2 gene (allele 4.2 Lisboa) associated with hereditary hemolytic anemia.</article-title>
                <source>Blood.</source>
                <year>1995</year>
                <volume>85</volume>
                <fpage>250</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">7803799</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.iolascon.1998.240">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Iolascon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miraglia del Giudice</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perrotta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alloisio</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morle</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delaunay</surname>
                    <given-names>J.</given-names>
                  </name>
                </person-group>
                <article-title>Hereditary spherocytosis: from clinical to molecular defects.</article-title>
                <source>Haematologica.</source>
                <year>1998</year>
                <volume>83</volume>
                <fpage>240</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">9573679</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.kanzaki.1997.522">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kanzaki</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayette</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morle</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuyama</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yawata</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wada</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vallier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alloisio</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yawata</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delaunay</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Total absence of protein 4.2 and partial deficiency of band 3 in hereditary spherocytosis.</article-title>
                <source>Br J Haematol.</source>
                <year>1997</year>
                <volume>99</volume>
                <fpage>522</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">9401060</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.kanzaki.1995.165">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kanzaki</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yawata</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yawata</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okamoto</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wada</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harano</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harano</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilmotte</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayette</surname>
                    <given-names>S.</given-names>
                  </name>
                </person-group>
                <article-title>Band 4.2 Komatsu: 523 GAT--&#x0003e;TAT (175 Asp--&#x0003e;Tyr) in exon 4 of the band 4.2 gene associated with total deficiency of band 4.2, hemolytic anemia with ovalostomatocytosis and marked disruption of the cytoskeletal network.</article-title>
                <source>Int J Hematol.</source>
                <year>1995</year>
                <volume>61</volume>
                <fpage>165</fpage>
                <lpage>78</lpage>
                <pub-id pub-id-type="pmid">8547605</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.korsgren.2010.4757">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Korsgren</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lux</surname>
                    <given-names>SE</given-names>
                  </name>
                </person-group>
                <article-title>Protein 4.2 binds to the carboxyl-terminal EF-hands of erythroid alpha-spectrin in a calcium- and calmodulin-dependent manner.</article-title>
                <source>J Biol Chem.</source>
                <year>2010</year>
                <volume>285</volume>
                <fpage>4757</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">20007969</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.mandal.2002.841">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mandal</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moitra</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basu</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Mapping of a spectrin-binding domain of human erythrocyte membrane protein 4.2.</article-title>
                <source>Biochem J.</source>
                <year>2002</year>
                <volume>364</volume>
                <fpage>841</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12049649</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.mentzer.1987.943">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mentzer</surname>
                    <given-names>WC</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Iarocci</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohandas</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lane</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lazerson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hays</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>Modulation of erythrocyte membrane mechanical stability by 2,3-diphosphoglycerate in the neonatal poikilocytosis/elliptocytosis syndrome.</article-title>
                <source>J Clin Invest.</source>
                <year>1987</year>
                <volume>79</volume>
                <fpage>943</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">3818955</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.mohandas.1982.768">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mohandas</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Health</surname>
                    <given-names>BP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolfe</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lux</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shohet</surname>
                    <given-names>SB</given-names>
                  </name>
                </person-group>
                <article-title>A technique to detect reduced mechanical stability of red cell membranes: relevance to elliptocytic disorders.</article-title>
                <source>Blood.</source>
                <year>1982</year>
                <volume>59</volume>
                <fpage>768</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">7059678</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.musallam.2013.64">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Musallam</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angastiniotis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eleftheriou</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porter</surname>
                    <given-names>JB</given-names>
                  </name>
                </person-group>
                <article-title>Cross-talk between available guidelines for the management of patients with beta-thalassemia major.</article-title>
                <source>Acta Haematol.</source>
                <year>2013</year>
                <volume>130</volume>
                <fpage>64</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">23485589</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.pajor.1993.37">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pajor</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehoczky</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szakacs</surname>
                    <given-names>Z</given-names>
                  </name>
                </person-group>
                <article-title>Pregnancy and hereditary spherocytosis. Report of 8 patients and a review.</article-title>
                <source>Arch Gynecol Obstet.</source>
                <year>1993</year>
                <volume>253</volume>
                <fpage>37</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">8328819</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.pekka_nuorti.2010">
              <mixed-citation publication-type="web">Pekka Nuorti J, Whitney CG. Prevention of Pneumococcal Disease Among Infants and Children -- Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/mmwr/pdf/rr/rr5911.pdf">online</ext-link>. 2010. Accessed 11-8-16.</mixed-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.perrotta.2008.1411">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Perrotta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallagher</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohandas</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Hereditary spherocytosis.</article-title>
                <source>Lancet.</source>
                <year>2008</year>
                <volume>372</volume>
                <fpage>1411</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">18940465</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.perrotta.1999.660">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Perrotta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iolascon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polito</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>d'Urzo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conte</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miraglia del Giudice</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>4.2 Nippon mutation in a non-Japanese patient with hereditary spherocytosis.</article-title>
                <source>Haematologica.</source>
                <year>1999</year>
                <volume>84</volume>
                <fpage>660</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">10406914</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.rice.2012.684">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rice</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crary</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langer</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kemper</surname>
                    <given-names>AR</given-names>
                  </name>
                </person-group>
                <article-title>Consortium ftSiCHA. Comparative effectiveness of different types of splenectomy for children with congenital hemolytic anemias.</article-title>
                <source>J Pediatr.</source>
                <year>2012</year>
                <volume>160</volume>
                <fpage>684</fpage>
                <lpage>9.e13</lpage>
                <pub-id pub-id-type="pmid">22050869</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.rice.2015.187">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rice</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Englum</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rothman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leonard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reiter</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thornburg</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brindle</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wright</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heeney</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smithers</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalfa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langer</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cada</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oldham</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St Peter</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharma</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davidoff</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nottage</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernabe</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dutta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glader</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crary</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dassinger</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunbar</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Islam</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rescorla</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruch</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Austin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidonio</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blakely</surname>
                    <given-names>ML</given-names>
                  </name>
                </person-group>
                <article-title>Splenectomy in Congenital Hemolytic Anemia C. Clinical outcomes of splenectomy in children: report of the splenectomy in congenital hemolytic anemia registry.</article-title>
                <source>Am J Hematol.</source>
                <year>2015</year>
                <volume>90</volume>
                <fpage>187</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">25382665</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.ruparel.2014.433">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ruparel</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bogert</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moir</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishitani</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khan</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zarroug</surname>
                    <given-names>AE</given-names>
                  </name>
                </person-group>
                <article-title>Synchronous splenectomy during cholecystectomy for hereditary spherocytosis: is it really necessary?</article-title>
                <source>J Pediatr Surg.</source>
                <year>2014</year>
                <volume>49</volume>
                <fpage>433</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">24650472</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.rybicki.1996.2745">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rybicki</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hustedt</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cobb</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <article-title>Increased rotational mobility and extractability of band 3 from protein 4.2-deficient erythrocyte membranes: evidence of a role for protein 4.2 in strengthening the band 3-cytoskeleton linkage.</article-title>
                <source>Blood.</source>
                <year>1996</year>
                <volume>88</volume>
                <fpage>2745</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">8839871</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.satchwell.2009.201">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Satchwell</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shoemark</surname>
                    <given-names>DK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sessions</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toye</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <article-title>Protein 4.2: a complex linker.</article-title>
                <source>Blood Cells Mol Dis.</source>
                <year>2009</year>
                <volume>42</volume>
                <fpage>201</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">19269200</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.su.2006.159">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Su</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ding</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jiang</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jiang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Z.</given-names>
                  </name>
                </person-group>
                <article-title>Associations of protein 4.2 with band 3 and ankyrin.</article-title>
                <source>Molecular and cellular biochemistry.</source>
                <year>2006</year>
                <volume>289</volume>
                <fpage>159</fpage>
                <lpage>66</lpage>
                <pub-id pub-id-type="pmid">16718373</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.takaoka.1994.527">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Takaoka</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ideguchi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakamoto</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takeuchi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukumaki</surname>
                    <given-names>Y.</given-names>
                  </name>
                </person-group>
                <article-title>A novel mutation in the erythrocyte protein 4.2 gene of Japanese patients with hereditary spherocytosis (protein 4.2 Fukuoka).</article-title>
                <source>Br J Haematol.</source>
                <year>1994</year>
                <volume>88</volume>
                <fpage>527</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">7819064</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.toye.2005.4088">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Toye</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghosh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>GK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sessions</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramauge</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leclerc</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delaunay</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanner</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <article-title>Protein-4.2 association with band 3 (AE1, SLCA4) in Xenopus oocytes: effects of three natural protein-4.2 mutations associated with hemolytic anemia.</article-title>
                <source>Blood.</source>
                <year>2005</year>
                <volume>105</volume>
                <fpage>4088</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">15692067</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.toye.2008.5380">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Toye</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williamson</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khanfar</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bader-Meunier</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cynober</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thibault</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tchernia</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dechaux</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delaunay</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruce</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <article-title>Band 3 Courcouronnes (Ser667Phe): a trafficking mutant differentially rescued by wild-type band 3 and glycophorin A.</article-title>
                <source>Blood.</source>
                <year>2008</year>
                <volume>111</volume>
                <fpage>5380</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18174378</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.van_den_akker.2010.1278">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van den Akker</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Satchwell</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pellegrin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flatt</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maigre</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daniels</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delaunay</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruce</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toye</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <article-title>Investigating the key membrane protein changes during in vitro erythropoiesis of protein 4.2 (-) cells (mutations Chartres 1 and 2).</article-title>
                <source>Haematologica.</source>
                <year>2010</year>
                <volume>95</volume>
                <fpage>1278</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">20179084</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.yawata.1994.131">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yawata</surname>
                    <given-names>Y.</given-names>
                  </name>
                </person-group>
                <article-title>Red cell membrane protein band 4.2: phenotypic, genetic and electron microscopic aspects.</article-title>
                <source>Biochim Biophys Acta.</source>
                <year>1994</year>
                <volume>1204</volume>
                <fpage>131</fpage>
                <lpage>48</lpage>
                <pub-id pub-id-type="pmid">8142452</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.yawata.2000.118">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yawata</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanzaki</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yawata</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doerfler</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozcan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eber</surname>
                    <given-names>SW</given-names>
                  </name>
                </person-group>
                <article-title>Characteristic features of the genotype and phenotype of hereditary spherocytosis in the Japanese population.</article-title>
                <source>Int J Hematol.</source>
                <year>2000</year>
                <volume>71</volume>
                <fpage>118</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">10745622</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="epb42-spherocytosis.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="epb42-spherocytosis.Suggested_Reading.reflist0">
            <ref id="epb42-spherocytosis.REF.cohen.1993.119">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dotimas</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korsgren</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Human erythrocyte membrane protein band 4.2 (pallidin).</article-title>
                <source>Semin Hematol.</source>
                <year>1993</year>
                <volume>30</volume>
                <fpage>119</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">8480187</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.dotimas.1993.19">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dotimas</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speicher</surname>
                    <given-names>DW</given-names>
                  </name>
                </person-group>
                <article-title>GuptaRoy B, Cohen CM. Structural domain mapping and phosphorylation of human erythrocyte pallidin (band 4.2).</article-title>
                <source>Biochim Biophys Acta.</source>
                <year>1993</year>
                <volume>1148</volume>
                <fpage>19</fpage>
                <lpage>29</lpage>
                <pub-id pub-id-type="pmid">8499466</pub-id>
              </element-citation>
            </ref>
            <ref id="epb42-spherocytosis.REF.korsgren.1988.10212">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Korsgren</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>CM</given-names>
                  </name>
                </person-group>
                <article-title>Associations of human erythrocyte band 4.2. Binding to ankyrin and to the cytoplasmic domain of band 3.</article-title>
                <source>J Biol Chem.</source>
                <year>1988</year>
                <volume>263</volume>
                <fpage>10212</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">2968981</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="epb42-spherocytosis.Author_Notes">
          <title>Author Notes</title>
          <p>
            <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cincinnatichildrens.org/bio/k/theodosia-kalfa/">Theodosia Kalfa, MD, PhD</ext-link>
          </p>
          <p>
            <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cincinnatichildrens.org/research/divisions/h/hematology/labs/kalfa/default/">Kalfa Lab</ext-link>
          </p>
        </sec>
        <sec id="epb42-spherocytosis.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>10 November 2016 (ma) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>13 March 2014 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>20 October 2013 (tk) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="epb42-spherocytosis.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Ektacytometry indicating a typical curve for HS (red), characterized by increased O<sub>min</sub> and decreased EI<sub>max</sub> and O<sub>hyp</sub> in comparison to normal control (blue). O<sub>min</sub> corresponds to the osmolality where 50% of the cells hemolyze in the osmotic fragility test and its value is affected by the surface area-to-volume ratio. EI<sub>max</sub> is the maximum elongation that the RBCs can achieve under shear stress and relates especially to the mechanical properties of the cytoskeleton. O<sub>hyp</sub> is the osmolality at which the EI is 50% of its maximum value and relates especially to the cytoplasmic viscosity [<xref ref-type="bibr" rid="epb42-spherocytosis.REF.mohandas.1982.768">Mohandas et al 1982</xref>].</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="epb42-spherocytosis-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
